Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13262936 | 0.85 | BRD4 (0.33) | BRD4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8422197 | 0.79 | ALDH1A1 (0.39) | ACHECHRNB2CHRNA4HTR2AHTR2C | |
| SCHEMBL1121711 | 0.79 | HTR2A (0.49) | CHRNB2CHRNA4SLC6A4HTR2AHTR2C | |
| SCHEMBL12303672 | 0.79 | HTR2A (0.49) | CHRNB2CHRNA4SLC6A4HTR2AHTR2C | |
| SCHEMBL29595508 | 0.79 | HTR2A (0.49) | CHRNB2CHRNA4SLC6A4HTR2AHTR2C | |
| SCHEMBL25696399 | 0.78 | CHRNB2 (0.38) | ACHECHRNB2CHRNA4SLC6A2SLC6A4 | |
| SCHEMBL13515613 | 0.78 | RAPGEF4 (0.33) | — | |
| SCHEMBL12511071 | 0.78 | RAPGEF4 (0.33) | — | |
| SCHEMBL21779355 | 0.77 | HTR1A (0.46) | — | |
| SCHEMBL4971608 | 0.77 | NISCH (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360760-A1 | Inhibitors of Bromodomains | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| WO-2016097863-A1 | INHIBITORS OF BROMODOMAINS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360760-A1 | Inhibitors of Bromodomains | BRDT, BRD3, BRPF3 | BRD4 5/4885ACHE 4734/4885CHRNB2 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.